物质信息
ID:351133
名称和标识
IUPAC传统名
tranilast
别名
Rizaben2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acidN-(3,4-Dimethoxycinnamoyl)anthranilic acid3,4-DAASB-252218Tranilast
IUPAC标准名
2-[3-(3,4-dimethoxyphenyl)prop-2-enamido]benzoic acid
化合物性质
安全信息
RTECS编号
DG8731000
危险公开号
22
个人保护装置
dust mask type N95 (US), Eyeshields, Gloves
欧盟危险性物质标志
有害性 (Xn)GHS危险品标识
急性毒性（口服，皮肤接触，吸入），类别4
皮肤刺激，类别2
眼刺激，类别2
皮肤过敏，类别1
特定目标器官毒性 -一次接触，类别3
MSDS下载
保存温度
2-8°C
GHS警示词
Warning
GHS危险声明
H302
德国WGK号
3
安全公开号
26-36
理化性质
溶解度
H2O: insoluble
DMSO: >10 mg/mL
熔点
166.2-168.2 °C(lit.)
外观
white to beige powder
产品相关信息
纯度
≥98% (HPLC)
Empirical Formula (Hill Notation)
C18H17NO5
药理学性质
相关基因信息
human ... VEGFA(7422), VEGFB(7423), VEGFC(7424)
描述信息
Biochem/physiol Actions
Tranilast is an anti-asthma drug, which inhibits LTC4 and PGE2 formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing TH1-mediated autoimmune diseases.
Tranilast is an anti-asthma drug, which inhibits LTC4 and PGE2 formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing TH1-mediated autoimmune diseases.
分子图谱
暂无数据
点击上传数据
参考文献
暂无数据
点击上传数据